Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072556 | 0.93 | TSHR (0.51) | TSHRNPSR1RXFP1POLBALOX15 | |
| SCHEMBL28931791 | 0.76 | SLC9A1 (0.42) | TSHRNPSR1RXFP1POLBALOX15 | |
| SCHEMBL28340453 | 0.76 | TSHR (0.42) | TSHRNPSR1RXFP1POLBALOX15 | |
| SCHEMBL4773425 | 0.75 | SIRT2 (0.41) | TSHRNPSR1RXFP1POLBALOX15 | |
| Trifluoroacetic Acid SCHEMBL4773422 | 0.75 | SIRT2 (0.41) | TSHRNPSR1RXFP1POLBALOX15 | |
| SCHEMBL13604184 | 0.75 | CHEK1 (0.40) | TSHRNPSR1POLBKMT2AALDH1A1 | |
| SCHEMBL17485144 | 0.75 | TSHR (0.41) | TSHRNPSR1RXFP1POLBALOX15 | |
| SCHEMBL3024121 | 0.74 | SLC9A1 (0.47) | TSHRNPSR1RXFP1POLBKMT2A | |
| SCHEMBL29389351 | 0.74 | TSHR (0.61) | TSHRNPSR1RXFP1POLBKMT2A | |
| SCHEMBL736439 | 0.74 | TSHR (0.61) | TSHRNPSR1RXFP1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110112114-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-04-28 | — | — | US | disclosed |
| US-7910568-B2 | Inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, gastrointestinal disorders; prevention/treatment of colon cancer; releases hydrogen sulfide | ANTIBE THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2009-09-17 | — | — | US | disclosed |
| US-7498355-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2009-03-03 | — | — | US | disclosed |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | ANTIBE THERAPEUTICS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | TSHR 4449/4885NPSR1 334/4885RXFP1 2796/4885 |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | CBS, SI, TST | TSHR 4651/4885NPSR1 359/4885RXFP1 3619/4885 |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | TSHR 4449/4885NPSR1 334/4885RXFP1 2796/4885 |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | TSHR 4449/4885NPSR1 334/4885RXFP1 2796/4885 |
| US-20110112114-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | HPN, PRSS1, PRSS3 | TSHR 4795/4885NPSR1 3261/4885RXFP1 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.